Revolution Medicines to Present Phase 3 Daraxonrasib PFS and OS Gains in Metastatic Pancreatic Cancer
Revolution Medicines will present Phase 3 RASolute 302 data showing daraxonrasib delivered statistically significant improvements in progression-free survival and overall survival versus standard intravenous chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma at the ASCO Plenary Session on May 31. The randomized trial met all primary and key secondary endpoints.
1. Clinical Trial Results
The RASolute 302 Phase 3 trial evaluated daraxonrasib 300 mg once daily versus investigator’s choice of standard intravenous cytotoxic chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. Topline data showed statistically significant and clinically meaningful improvements in both progression-free survival and overall survival, marking an unprecedented OS benefit in this patient population.
2. ASCO Presentation Details
Detailed results will be presented at the American Society of Clinical Oncology Annual Meeting during a Plenary Session on May 31, 2026, at McCormick Place in Chicago. Brian M. Wolpin, M.D., M.P.H., of Dana-Farber Cancer Institute will deliver the 12-minute presentation beginning at 3:21 PM CDT in Hall B1.
3. Trial Design and Drug Profile
RASolute 302 is a global, randomized registrational trial enrolling patients with RAS G12 mutations and wild-type tumors. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor with Breakthrough Therapy and Orphan Drug designations, targeting diverse RAS-addicted cancers and currently being evaluated across multiple Phase 3 studies.